Is Perrigo (PRGO) overvalued or fairly valued?

MarketChacha shows Perrigo's valuation in context — a forward P/E of about 6.2, a price-to-book of about 0.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Perrigo's revenue?

Perrigo reported revenue of $4.3B for FY2025, with net profit of $-1.4B, per official filings.

What is the share price of Perrigo (PRGO)?

Perrigo last traded at $14.92 (+4.6% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Perrigo

PRGO · NYSE · Healthcare · United States

Snapshot

TickerPRGO

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees8,100

HeadquartersDublin, Ireland

Websitewww.perrigo.com

Filings tracked18

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Who owns it

Insiders0.4%
Institutions99.6%
Public & other0.0%

435 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.36%
Neuberger Berman Group, LLC7.70%
Vanguard Portfolio Management LLC6.52%
Price (T.Rowe) Associates Inc6.27%
State Street Corporation6.15%
Fuller & Thaler Asset Management Inc.5.40%
Vanguard Capital Management LLC4.50%
Invesco Ltd.4.23%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 33.2 points over the period — profitability is trending down.

Net margin trend-0.3% → -33.5%

Margin has compressed by about 33.2 points over the period — profitability is trending down.

Return on equity-48.6%

Latest ROE of -48.6% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.1B · EPS 0.74

Est. earnings growth -3.8%

Next fiscal year

Rev $4.1B · EPS 2.40

Est. earnings growth +9.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$4.3B

Net margin

-33.5%

ROE

-48.6%

Revenue CAGR (2y)

-4.4%

EPS (FY2025)

-10.29

Net profit (FY2025)

$-1.4B

Ask MarketChacha about PRGO

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$4.3B	$-1.4B	-10.29	-33.5%	-48.6%
FY2024	$4.4B	$-171.8M	-1.25	-3.9%	-4.0%
FY2023	$4.7B	$-12.7M	-0.09	-0.3%	-0.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.0B	$74.5M	0.53	7.3%
2026Q1	$969.2M	$-398.6M	-2.87	-41.1%
2025Q3	$1.0B	$7.5M	0.05	0.7%
2025Q2	$1.1B	$-8.4M	-0.06	-0.8%
2025Q1	$1.0B	$-6.4M	-0.05	-0.6%
2024Q3	$1.1B	$-21.0M	-0.15	-1.9%
2024Q2	$1.1B	$-108.4M	-0.79	-10.2%
2024Q1	$1.1B	$2.0M	0.01	0.2%
2023Q3	$1.1B	$8.4M	0.10	0.7%
2023Q2	$1.2B	$-3.0M	-0.02	-0.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC8/5/2026material
8-K — Executive/director change
SEC7/6/2026material
8-K/A — Executive/director change, Exhibits
SEC7/6/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/30/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/8/2026material
8-K — Results of operations, Exhibits
SEC5/6/2026material
10-Q filing
SEC5/6/2026
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/5/2026material
8-K — Completion of acquisition/disposition, Reg FD disclosure, Exhibits
SEC4/30/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/22/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC3/23/2026material
8-K — Results of operations, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026

2025

8-K — Results of operations, Reg FD disclosure
SEC11/5/2025material
10-Q filing
SEC11/5/2025
8-K — Results of operations, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.